Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · see citing works

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155 · see citing works

The blockade of immune checkpoints in cancer immunotherapy

Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · see citing works

Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer

Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works

Elements of cancer immunity and the cancer–immune set point

Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · see citing works

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231 · see citing works

Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial

Rittmeyer, A., Barlési, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Cobo, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,684 · see citing works

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669 · see citing works

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,373 · see citing works

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214 · see citing works

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756 · see citing works

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics

Seymour, L., Bogaerts, J., Perrone, A., Ford, R., Schwartz, L. H., Mandrekar, S., Lin, N. U., Litière, S., Dancey, J., Chen, A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30074-8 · Cited by 2,472 · see citing works

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

Powles, T. B., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Joaquim Bellmunt, B., Burris, H. A., Petrylak, D. P., Teng, S.-L. M., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,383 · see citing works

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Robert, C., Ribas, A., Wolchok, J. D., Hodi, F. S., Hamid, O., Kefford, R., Weber, J. S., Joshua, A. M., Hwu, W.-J., Gangadhar, T. C., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60958-2 · Cited by 1,774 · see citing works

Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1

Champiat, S., Dercle, L., Ammari, S., Massard, C., Hollebecque, A., Postel-Vinay, S. C., Chaput, N., Eggermont, A. M. M., Marabelle, A., Soria, J., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1741 · Cited by 1,188 · see citing works

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

Motzer, R. J., Rini, B. I., McDermott, D. F., Redman, B. G., Kuzel, T. M., Harrison, M. R., Vaishampayan, U. N., Drabkin, H. A., George, S., Logan, T. F., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0703 · Cited by 1,074 · see citing works

Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate

(2017) · doi:10.1158/1078-0432.ccr-16-3133 · Cited by 831 · see citing works

Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab

Hodi, F. S., Hwu, W., Kefford, R. F., Weber, J. S., DAUD, A. I., Hamid, O., Patnaik, A., Ribas, A., Robert, C., Gangadhar, T. C., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.0391 · Cited by 735 · see citing works

Developing a common language for tumor response to immunotherapy: immune-related response criteria using unidimensional measurements

Nishino, M., Giobbie-Hurder, A., Gargano, M., Suda, M., Ramaiya, N. H., & Hodi, F. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0895 · Cited by 522 · see citing works

Improved Endpoints for Cancer Immunotherapy Trials

Hoos, A., Eggermont, A. M. M., Janetzki, S., Hodi, F. S., Ibrahim, R. A., Anderson, A., Humphrey, R. W., Blumenstein, B. A., Old, L. J., & Wolchok, J. D. (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq310 · Cited by 517 · see citing works

Interobserver and intraobserver variability in measurement of non-small-cell carcinoma lung lesions: implications for assessment of tumor response.

Erasmus, J., Gladish, G., Broemeling, L., Sabloff, B., Truong, M., Herbst, R., & Munden, R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.01.144 · Cited by 489 · see citing works

Challenges of Guarantee-Time Bias

Giobbie‐Hurder, A., Gelber, R. D., & Regan, M. M. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.5283 · Cited by 463 · see citing works

Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

Peters, S., Gettinger, S. N., Johnson, M. L., Janne, P. A., Garassino, M. C., Christoph, D. C., Toh, C., Rizvi, N. A., Chaft, J. E., Carcereny, E., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.9476 · Cited by 400 · see citing works

Evaluating Variability in Tumor Measurements from Same-day Repeat CT Scans of Patients with Non–Small Cell Lung Cancer

Zhao, B., James, L. P., Moskowitz, C. S., Guo, P., Ginsberg, M. S., Lefkowitz, R. A., Qin, Y., Riely, G. J., Kris, M. G., & Schwartz, L. H. (2009) · Radiology · doi:10.1148/radiol.2522081593 · Cited by 337 · see citing works

PD-1 and PD-L1 antibodies in cancer: current status and future directions

Balar, A. V., & Weber, J. S. (2017) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-017-1954-6 · Cited by 299 · see citing works

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases

Giacomo, A. M. D., Danielli, R., Guidoboni, M., Calabrò, L., Carlucci, D., Miracco, C., Volterrani, L., Mazzei, M. A., BIAGIOLI, M., Altomonte, M., et al. (2009) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0642-y · Cited by 287 · see citing works

Variability of Lung Tumor Measurements on Repeat Computed Tomography Scans Taken Within 15 Minutes

Oxnard, G. R., Zhao, B., Sima, C. S., Ginsberg, M. S., James, L. P., Lefkowitz, R. A., Guo, P., Kris, M. G., Schwartz, L. H., & Riely, G. J. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7071 · Cited by 161 · see citing works

Cancer immunotherapy and immune-related response assessment: The role of radiologists in the new arena of cancer treatment

Nishino, M., Tirumani, S. H., Ramaiya, N. H., & Hodi, F. S. (2015) · European Journal of Radiology · doi:10.1016/j.ejrad.2015.03.017 · Cited by 115 · see citing works

Immune-related response assessment during PD-1 inhibitor therapy in advanced non-small-cell lung cancer patients

Nishino, M., Ramaiya, N. H., Chambers, E. S., Adeni, A. E., Hatabu, H., Janne, P. A., Hodi, F. S., & Awad, M. M. (2016) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-016-0193-2 · Cited by 115 · see citing works

CT Tumor Volume Measurement in Advanced Non-small-cell Lung Cancer

Nishino, M., Guo, M., Jackman, D. M., DiPiro, P. J., Yap, J. T., Ho, T. T. N., Hatabu, H., Janne, P. A., den Abbeele, A. D. V., & Johnson, B. E. (2010) · Academic Radiology · doi:10.1016/j.acra.2010.08.021 · Cited by 82 · see citing works

CCR 20th Anniversary Commentary: Immune-Related Response Criteria—Capturing Clinical Activity in Immuno-Oncology

Hoos, A., Wolchok, J. D., Humphrey, R. W., & Hodi, F. S. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3128 · Cited by 61 · see citing works

Response assessment in metastatic melanoma treated with ipilimumab and bevacizumab: CT tumor size and density as markers for response and outcome

Nishino, M., Giobbie‐Hurder, A., Ramaiya, N. H., & Hodi, F. S. (2014) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-014-0040-2 · Cited by 61 · see citing works

Non-classical response measured by immune-modified RECIST and post-progression treatment effects of atezolizumab in 2L/3L NSCLC: Results from the randomized phase II study POPLAR.

Mazières, J., Fehrenbacher, L., Rittmeyer, A., Spira, A. I., Park, K., Smith, D. A. B., Artal, A., Lewanski, C. R., Braiteh, F. S., Yi, J., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.34.15_suppl.9032 · Cited by 19 · see citing works

Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Planchard, D., Popat, S., Kerr, K., Novello, S., Smit, E. F., Faivre-Finn, C., Mok, T. S., Reck, M., Van Schil, P. E., Hellmann, M. D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy275 · Cited by 2,274 · see citing works

Top 10 Challenges in Cancer Immunotherapy

Hegde, P. S., & Chen, D. S. (2020) · Immunity · doi:10.1016/j.immuni.2019.12.011 · Cited by 2,238 · see citing works

Immunotherapies for hepatocellular carcinoma

Llovet, J. M., Castet, F., Heikenwalder, M., Maini, M. K., Mazzaferro, V., Pinato, D. J., Pikarsky, E., Zhu, A. X., & Finn, R. S. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00573-2 · Cited by 1,843 · see citing works

TGFβ biology in cancer progression and immunotherapy

Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944 · see citing works

A phase Ib trial of personalized neoantigen therapy plus anti-PD-1 in patients with advanced melanoma, non-small cell lung cancer, or bladder cancer

Ott, P. A., Hu-Lieskovan, S., Chmielowski, B., Govindan, R., Naing, A., Bhardwaj, N., Margolin, K., Awad, M. M., Hellmann, M. D., Lin, J. J., et al. (2020) · Cell · doi:10.1016/j.cell.2020.08.053 · Cited by 738 · see citing works

mRECIST for HCC: Performance and novel refinements

Llovet, J. M., & Lencioni, R. A. (2020) · Journal of Hepatology · doi:10.1016/j.jhep.2019.09.026 · Cited by 689 · see citing works

Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Hendriks, L. E. L., Kerr, K. M., Menis, J., Mok, T. S. K., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 644 · see citing works

Novel patterns of response under immunotherapy

Borcoman, É., Kanjanapan, Y., Champiat, S., Kato, S., Servois, V., Kurzrock, R., Goel, S., Bedard, P. L., & Tourneau, C. L. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz003 · Cited by 519 · see citing works

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference

Llovet, J. M., Villanueva, A., Marrero, J. A., Schwartz, M., Meyer, T., Galle, P. R., Lencioni, R., Greten, T. F., Kudo, M., Mandrekar, S. J., et al. (2021) · Hepatology · doi:10.1002/hep.31327 · Cited by 413 · see citing works

Systemic immune‐inflammation index, neutrophil‐to‐lymphocyte ratio, platelet‐to‐lymphocyte ratio can predict clinical outcomes in patients with metastatic non‐small‐cell lung cancer treated with nivolumab

Liu, J., Li, S., Zhang, S., Liu, Y., Ma, L., Zhu, J., Xin, Y., Wang, Y., Yang, C., & Cheng, Y. (2019) · Journal of Clinical Laboratory Analysis · doi:10.1002/jcla.22964 · Cited by 364 · see citing works

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

Korean Liver Cancer Association (KLCA), & National Cancer Center (NCC) Korea (2022) · Clinical and Molecular Hepatology · doi:10.3350/cmh.2022.0294 · Cited by 350 · see citing works

Pan-Asian adapted Clinical Practice Guidelines for the management of patients with metastatic non-small-cell lung cancer: a CSCO–ESMO initiative endorsed by JSMO, KSMO, MOS, SSO and TOS

Wu, Y.-L., Planchard, D., Lü, S., Sun, H., Yamamoto, N., Kim, D., Tan, D. S.-W., Yang, J. C., Azrif, M., Mitsudomi, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy554 · Cited by 292 · see citing works

Immunotherapy of Melanoma: Facts and Hopes

Weiss, S. A., Wolchok, J. D., & Sznol, M. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1550 · Cited by 279 · see citing works

The society for immunotherapy of cancer consensus statement on immunotherapy for the treatment of advanced renal cell carcinoma (RCC)

Rini, B. I., Battle, D. J., Figlin, R. A., George, D. J., Hammers, H. J., Hutson, T., Jonasch, E. W., Joseph, R. W., McDermott, D. F., Motzer, R. J., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0813-8 · Cited by 254 · see citing works

Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival

Llovet, J. M., Montal, R., & Villanueva, A. (2019) · Journal of Hepatology · doi:10.1016/j.jhep.2019.01.028 · Cited by 233 · see citing works

BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update

Reig, M., Sanduzzi‐Zamparelli, M., Forner, A., Rimola, J., Ferrer, J., Burrel, M., García‐Criado, Á., Díaz, A., Llarch, N., Iserte, G., et al. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.10.020 · Cited by 253 · see citing works

Effect of immunotherapy time-of-day infusion on overall survival among patients with advanced melanoma in the USA (MEMOIR): a propensity score-matched analysis of a single-centre, longitudinal study

Qian, D. C., Kleber, T., Brammer, B., Xu, K. M., Switchenko, J. M., Janopaul-Naylor, J. R., Zhong, J., Yushak, M. L., Harvey, R. D., Paulos, C. M., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(21)00546-5 · Cited by 223 · see citing works

Resumption of Immune Checkpoint Inhibitor Therapy After Immune-Mediated Colitis

Abu‐Sbeih, H., Ali, F. S., Naqash, A. R., Owen, D. H., Patel, S. H., Otterson, G. A., Kendra, K. L., Ricciuti, B., Chiari, R., Giglio, A. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00320 · Cited by 199 · see citing works

The potential mechanism, recognition and clinical significance of tumor pseudoprogression after immunotherapy

Jia, W., Gao, Q., Han, A., Zhu, H., & Yu, J. (2019) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0144 · Cited by 194 · see citing works

Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis

Abu-Sbeih, H., Ali, F. S., Wang, X., Mallepally, N., Chen, E., Altan, M., Bresalier, R. S., Charabaty, A., Dadu, R., Jazaeri, A., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0577-1 · Cited by 191 · see citing works

Intersection of immune and oncometabolic pathways drives cancer hyperprogression during immunotherapy

Li, G., Choi, J. E., Kryczek, I., Sun, Y., Liao, P., Li, S., Wei, S., Grove, S., Vatan, L., Nelson, R., et al. (2023) · Cancer Cell · doi:10.1016/j.ccell.2022.12.008 · Cited by 160 · see citing works

Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study

Gandara, D. R., von Pawel, J., Mazières, J., Sullivan, R., Helland, Å., Han, J., Ponce-Aix, S., Rittmeyer, A., Barlési, F., Kubo, T., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.08.2027 · Cited by 156 · see citing works

The Promise of Combining Radiation Therapy With Immunotherapy

Jagodinsky, J. C., Harari, P. M., & Morris, Z. S. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.04.023 · Cited by 144 · see citing works

High-affinity neoantigens correlate with better prognosis and trigger potent antihepatocellular carcinoma (HCC) activity by activating CD39 + CD8 + T cells

Liu, T., Tan, J., Wu, M., Fan, W., Wei, J., Zhu, B., Guo, J. M., Wang, S., Zhou, P., Zhang, H., et al. (2020) · Gut · doi:10.1136/gutjnl-2020-322196 · Cited by 139 · see citing works

2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma

(2022) · Korean Journal of Radiology · doi:10.3348/kjr.2022.0822 · Cited by 138 · see citing works

2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma

(2022) · Journal of Liver Cancer · doi:10.17998/jlc.2022.11.07 · Cited by 137 · see citing works

The beginning of the end for conventional RECIST — novel therapies require novel imaging approaches

Gerwing, M., Herrmann, K., Helfen, A., Schliemann, C., Berdel, W. E., Eisenblätter, M., & Wildgruber, M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0169-5 · Cited by 127 · see citing works

Efficacy and safety of vedolizumab and infliximab treatment for immune-mediated diarrhea and colitis in patients with cancer: a two-center observational study

Zou, F., Faleck, D. M., Thomas, A. S., Harris, J., Satish, D., Wang, X., Charabaty, A., Ernstoff, M. S., Oliva, I. C. G., Hanauer, S. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003277 · Cited by 126 · see citing works

Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy

Fujimoto, D., Yoshioka, H., Kataoka, Y., Morimoto, T., Hata, T., Kim, Y. H., Tomii, K., Ishida, T., Hirabayashi, M., Hara, S., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.167 · Cited by 119 · see citing works

Joint EANM/SNMMI/ANZSNM practice guidelines/procedure standards on recommended use of [18F]FDG PET/CT imaging during immunomodulatory treatments in patients with solid tumors version 1.0

Lopci, E., Hicks, R. J., Dimitrakopoulou‐Strauss, A., Dercle, L., Iravani, A., Seban, R., Sachpekidis, C., Humbert, O., Gheysens, O. S., Glaudemans, A. W. J. M., et al. (2022) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-022-05780-2 · Cited by 116 · see citing works

Radiologic Pseudoprogression during Anti–PD-1 Therapy for Advanced Non–Small Cell Lung Cancer

Katz, S. I., Hammer, M. M., Bagley, S. J., Aggarwal, C., Bauml, J. M., Thompson, J. C., Nachiappan, A. C., Simone, C. B., & Langer, C. J. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.010 · Cited by 113 · see citing works

irRECIST for the Evaluation of Candidate Biomarkers of Response to Nivolumab in Metastatic Clear Cell Renal Cell Carcinoma: Analysis of a Phase II Prospective Clinical Trial

Pignon, J., Jegede, O. A., Shukla, S. A., Braun, D. A., Horak, C. E., Wind‐Rotolo, M., Ishii, Y., Catalano, P. J., Grosha, J., Flaifel, A., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3206 · Cited by 113 · see citing works

Hyperacute rejection-engineered oncolytic virus for interventional clinical trial in refractory cancer patients

Zhong, L., Gan, L., Wang, B., Wu, T., Yao, F., Gong, W., Peng, H., Deng, Z., Xiao, G., Liu, X., et al. (2025) · Cell · doi:10.1016/j.cell.2024.12.010 · Cited by 107 · see citing works

Radioimmunotherapy for the treatment of head and neck cancer.

Karam, S., & Raben, D. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30306-7 · Cited by 81 · see citing works

Nivolumab treatment beyond RECIST‐defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial

Haddad, R. I., Concha‐Benavente, F., Blumenschein, G. R., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L. F., Kasper, S., Vokes, E. E., Worden, F. P., et al. (2019) · Cancer · doi:10.1002/cncr.32190 · Cited by 99 · see citing works

Imaging of tumour response to immunotherapy

Dromain, C., Beigelman‐Aubry, C., Pozzessere, C., Durán, R., & Digklia, A. (2020) · European Radiology Experimental · doi:10.1186/s41747-019-0134-1 · Cited by 98 · see citing works

Objective response rate assessment in oncology: Current situation and future expectations

Aykan, N. F., & Özatlı, T. (2020) · World Journal of Clinical Oncology · doi:10.5306/wjco.v11.i2.53 · Cited by 97 · see citing works

Pseudoprogression and Hyperprogression as New Forms of Response to Immunotherapy

Frélaut, M., du Rusquec, P., Moura, A. D., Tourneau, C. L., & Borcoman, É. (2020) · BioDrugs · doi:10.1007/s40259-020-00425-y · Cited by 99 · see citing works

Immunotherapy for Head and Neck Cancer: A Paradigm Shift From Induction Chemotherapy to Neoadjuvant Immunotherapy

Shibata, H., Saito, S., & Uppaluri, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.727433 · Cited by 96 · see citing works

The Cancer Immunotherapy Biomarker Testing Landscape

Walk, E. E., Yohe, S. L., Beckman, A., Schade, A. E., Zutter, M. M., Pfeifer, J. D., & Berry, A. B. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2018-0584-cp · Cited by 94 · see citing works

Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies

Walsh, R. J., & Soo, R. A. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920937902 · Cited by 92 · see citing works

Imaging for the diagnosis and response assessment of renal tumours

Rossi, S. H., Prezzi, D., Kelly‐Morland, C., & Goh, V. (2018) · World Journal of Urology · doi:10.1007/s00345-018-2342-3 · Cited by 91 · see citing works

Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma

Abu‐Sbeih, H., Ali, F. S., Qiao, W., Lü, Y., Patel, S. P., Diab, A. K., & Wang, Y. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02303-1 · Cited by 88 · see citing works

IGFBP2 regulates PD-L1 expression by activating the EGFR-STAT3 signaling pathway in malignant melanoma

Li, T., Zhang, C., Zhao, G., Zhang, X., Hao, M., Hassan, S., Zhang, M., Zheng, H., Yang, D., Liu, L., et al. (2020) · Cancer Letters · doi:10.1016/j.canlet.2020.02.036 · Cited by 85 · see citing works

Targeting the PD-1/PD-L1 Pathway in Renal Cell Carcinoma

Kammerer‐Jacquet, S., Deleuze, A., Saout, J., Mathiéu, R., Laguerre, B., Verhoest, G., Dugay, F., Belaud‐Rotureau, M., Bensalah, K., & Rioux-Leclercq, N. C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20071692 · Cited by 86 · see citing works

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer

Emens, L. A., Adams, S., Cimino‐Mathews, A., Disis, M. L., Gatti-Mays, M. E., Ho, A. Y., Kalinsky, K. M., McArthur, H. L., Mittendorf, E. A., Nanda, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002597 · Cited by 84 · see citing works

Progress and Opportunities to Advance Clinical Cancer Therapeutics Using Tumor Dynamic Models

Bruno, R., Bottino, D. C., de Alwis, D. P., Fojo, A. T., Guedj, J., Liu, C., Swanson, K. R., Zheng, J., Zheng, Y., & Jin, J. Y. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0287 · Cited by 85 · see citing works

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis

Mulkey, F. A., Theoret, M. R., Keegan, P., Pazdur, R., & Sridhara, R. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000146 · Cited by 81 · see citing works

Quantitative PET imaging of PD-L1 expression in xenograft and syngeneic tumour models using a site-specifically labelled PD-L1 antibody

Christensen, C. L., Kristensen, L. K., Alfsen, M. Z., Nielsen, C. H., & Kjær, A. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04646-4 · Cited by 80 · see citing works

In vivo Imaging Technologies to Monitor the Immune System

McCarthy, C. E., White, J. M., Viola, N. T., & Gibson, H. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01067 · Cited by 80 · see citing works

STAT5 and STAT3 balance shapes dendritic cell function and tumour immunity

Zhou, J., Tison, K., Zhou, H., Bai, L., Acharyya, R. K., McEachern, D., Metwally, H., Wang, Y., Pitter, M. R., Choi, J. E., et al. (2025) · Nature · doi:10.1038/s41586-025-09000-3 · Cited by 79 · see citing works

New Era in the Management of Melanoma Brain Metastases

Tawbi, H. A., Boutros, C., Kok, D. L., Robert, C., & McArthur, G. A. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200819 · Cited by 78 · see citing works

Melanoma brain metastases – Interdisciplinary management recommendations 2020

Gutzmer, R., Vordermark, D., Hassel, J. C., Krex, D., Wendl, C. M., Schadendorf, D., Sickmann, T., Rieken, S., Pukrop, T., Höeller, C., et al. (2020) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2020.102083 · Cited by 72 · see citing works

Immunotherapy by Immune Checkpoint Inhibitors and Nuclear Medicine Imaging: Current and Future Applications

Decazes, P., & Bohn, P. (2020) · Cancers · doi:10.3390/cancers12020371 · Cited by 63 · see citing works

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of melanoma, version 3.0

Pavlick, A. C., Ariyan, C. E., Buchbinder, E. I., Davar, D., Gibney, G. T., Hamid, O., Hieken, T. J., Izar, B., Johnson, D. B., Kulkarni, R. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-006947 · Cited by 72 · see citing works

MRI of tumor T cell infiltration in response to checkpoint inhibitor therapy

Jiang, X., Dudzinski, S. O., Beckermann, K. E., Young, K. L., McKinley, E. T., McIntyre, J. O., Rathmell, J. C., Xu, J., & Gore, J. C. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000328 · Cited by 65 · see citing works

SHR-1701, a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, for Recurrent or Metastatic Cervical Cancer: A Clinical Expansion Cohort of a Phase I Study

Feng, J., Tang, D., Wang, J., Zhou, Q., Peng, J., Lou, H., Sun, Y., Cai, Y., Chen, H., Yang, J., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-0346 · Cited by 63 · see citing works

Cabozantinib in combination with atezolizumab versus sorafenib in treatment-naive advanced hepatocellular carcinoma: COSMIC-312 Phase III study design

Kelley, R. K., Oliver, J. W., Hazra, S., Benzaghou, F., Yau, T. C. C., Cheng, A., & Rimassa, L. (2020) · Future Oncology · doi:10.2217/fon-2020-0283 · Cited by 62 · see citing works

Cancer immunotherapy: the art of targeting the tumor immune microenvironment

da Silva, J. L., dos Santos, A. L. S., Nunes, N. C. C., da Silva, F. D. M. L., Ferreira, C. G., & de Melo, A. C. (2019) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-019-03894-3 · Cited by 61 · see citing works

Revised European Society of Endocrinology Clinical Practice Guideline for the management of aggressive pituitary tumours and pituitary carcinomas

Raverot, G., Burman, P., Abreu, A. P., Heaney, A. P., van Hulsteijn, L. T., Lin, A. L., Marcus, H. J., McCormack, A. I., Minniti, G., Petersenn, S., et al. (2025) · European Journal of Endocrinology · doi:10.1093/ejendo/lvaf100 · Cited by 66 · see citing works

Tumor response assessment on imaging following immunotherapy

Berz, A. M., Dromain, C., Violi, N. V., Boughdad, S., & Durán, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.982983 · Cited by 60 · see citing works

Disease Etiology and Outcomes After Atezolizumab Plus Bevacizumab in Hepatocellular Carcinoma: Post-Hoc Analysis of IMbrave150

Espinoza, M., Muquith, M., Lim, M., Zhu, H., Singal, A. G., & Hsiehchen, D. (2023) · Gastroenterology · doi:10.1053/j.gastro.2023.02.042 · Cited by 55 · see citing works

MR cell size imaging with temporal diffusion spectroscopy

Jiang, X., Li, H., Devan, S. P., Gore, J. C., & Xu, J. (2020) · Magnetic Resonance Imaging · doi:10.1016/j.mri.2020.12.010 · Cited by 54 · see citing works

Realizing the promise of Project Optimus: Challenges and emerging opportunities for dose optimization in oncology drug development

Gao, W., Liu, J., Shtylla, B., Venkatakrishnan, K., Yin, D., Shah, M., Nicholas, T., & Cao, Y. (2023) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.13079 · Cited by 54 · see citing works

Long Non-Coding RNA DUXAP8 Enhances Renal Cell Carcinoma Progression via Downregulating miR-126

Huang, T., Wang, X., Yang, X., Ji, J., Wang, Q., Yue, X., & Dong, Z. (2018) · Medical Science Monitor · doi:10.12659/msm.910054 · Cited by 52 · see citing works

Imaging the Cancer Immune Environment and Its Response to Pharmacologic Intervention, Part 1: The Role of 18F-FDG PET/CT

Iravani, A., & Hicks, R. J. (2020) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.234278 · Cited by 52 · see citing works

PET/CT imaging for evaluation of multimodal treatment efficacy and toxicity in advanced NSCLC—current state and future directions

Eze, C., Schmidt-Hegemann, N.-S., Sawicki, L. M., Kirchner, J., Roengvoraphoj, O., Käsmann, L., Mittlmeier, L. M., Kunz, W. G., Tufman, A., Dinkel, J., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05211-8 · Cited by 52 · see citing works

Safety and immunogenicity of novel 5T4 viral vectored vaccination regimens in early stage prostate cancer: a phase I clinical trial

Cappuccini, F., Bryant, R. J., Pollock, E., Carter, L. M., Verrill, C. L., Hollidge, J., Poulton, I. D., Baker, M., Mitton, C. H., Baines, A. C., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000928 · Cited by 49 · see citing works

The potential of breath analysis to improve outcome for patients with lung cancer

Antoniou, S., Gaude, E., Ruparel, M., van der Schee, M. P., Janes, S. M., & Rintoul, R. C. (2019) · Journal of Breath Research · doi:10.1088/1752-7163/ab0bee · Cited by 49 · see citing works

The Future of Cancer Diagnosis, Treatment and Surveillance: A Systemic Review on Immunotherapy and Immuno-PET Radiotracers

Liberini, V., Laudicella, R., Capozza, M., Huellner, M. W., Burger, I. A., Baldari, S., Terreno, E., & Deandreis, D. (2021) · Molecules · doi:10.3390/molecules26082201 · Cited by 48 · see citing works

Impact of immunotherapy time-of-day infusion on survival and immunologic correlates in patients with metastatic renal cell carcinoma: a multicenter cohort analysis

Patel, J. S., Woo, Y., Draper, A., Jansen, C. S., Carlisle, J. W., Innominato, P. F., Lévi, F., Dhabaan, L., Master, V. A., Bilen, M. A., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-008011 · Cited by 47 · see citing works

Artificial Intelligence-based Radiomics in the Era of Immuno-oncology

Kang, C., Duarte, S. E., Kim, H. S., Kim, E., Park, J., Lee, A., Kim, Y., Kim, L., Cho, S., Oh, Y., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac036 · Cited by 42 · see citing works

Immunotherapy for the Treatment of Breast Cancer: Emerging New Data

Mina, L. A., Lim, S., Bahadur, S. W., & Firoz, A. T. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s184710 · Cited by 54 · see citing works

A CT-Based Radiomics Approach to Predict Nivolumab Response in Advanced Non-Small-Cell Lung Cancer

Liu, C., Gong, J., Yu, H., LIU, Q., Wang, S.-P., & Wang, J.-L. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.544339 · Cited by 41 · see citing works

MRI-based radiomics for prognosis of pediatric diffuse intrinsic pontine glioma: an international study

Tam, L. T., Yeom, K. W., Wright, J. N., Jaju, A. I., Radmanesh, A., Han, M., Toescu, S. M., Maleki, M., Chen, E., Campion, A., et al. (2021) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdab042 · Cited by 42 · see citing works

CAR T-Cell Therapy: An Update for Radiologists

Yoon, J. G., Smith, D. A., Tirumani, S. H., Caimi, P. F., & Ramaiya, N. H. (2021) · American Journal of Roentgenology · doi:10.2214/ajr.21.26091 · Cited by 43 · see citing works

Imaging approaches and radiomics: toward a new era of ultraprecision radioimmunotherapy?

Sun, R., Henry, T., Laville, A., Carré, A., Hamaoui, A., Bockel, S., Chaffai, I., Lévy, A., Chargari, C., Robert, C., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004848 · Cited by 31 · see citing works

The Role of Immune Checkpoint Inhibitors in Cancer Therapy: Mechanism and Therapeutic Advances

Chen, H., Yang, H., Guo, L., & Sun, Q. (2025) · MedComm · doi:10.1002/mco2.70412 · Cited by 45 · see citing works

Pilot Study of CT-Based Radiomics Model for Early Evaluation of Response to Immunotherapy in Patients With Metastatic Melanoma

Wang, Z., Mao, L., Zhou, Z., Si, L., Zhu, H., Chen, X., Zhou, M., Sun, Y., & Guo, J. X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01524 · Cited by 41 · see citing works

Pseudoprogression in lung cancer patients treated with immunotherapy

Chen, M., & Zeng, Y. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2021.103531 · Cited by 41 · see citing works

Immunotherapy: Recent Advances and Its Future as a Neoadjuvant, Adjuvant, and Primary Treatment in Colorectal Cancer

Yu, I., Dakwar, A., & Takabe, K. (2023) · Cells · doi:10.3390/cells12020258 · Cited by 40 · see citing works

Immunotherapy Targeting PD-1/PD-L1 in Early-Stage Triple-Negative Breast Cancer

Yang, T.-L., Li, W., Huang, T., & Zhou, J. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13030526 · Cited by 41 · see citing works

In silico cancer immunotherapy trials uncover the consequences of therapy-specific response patterns for clinical trial design and outcome

Creemers, J. H. A., Ankan, A., Roes, K. C. B., Schröder, G., Mehra, N., Figdor, C. G., de Vries, I. J. M., & Textor, J. C. (2023) · Nature Communications · doi:10.1038/s41467-023-37933-8 · Cited by 39 · see citing works

Dissociated responses at initial computed tomography evaluation is a good prognostic factor in non-small cell lung cancer patients treated with anti-programmed cell death-1/ligand 1 inhibitors

Tozuka, T., Kitazono, S., Sakamoto, H., Yoshida, H., Amino, Y., Uematsu, S., Yoshizawa, T., Hasegawa, T., Uchibori, K., Yanagitani, N., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-6704-z · Cited by 40 · see citing works

Immune checkpoint inhibitors in esophageal squamous cell carcinoma: progress and opportunities

Jiao, R., Luo, H., Xu, W., & Ge, H. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s214579 · Cited by 39 · see citing works

iRECIST and atypical patterns of response to immuno-oncology drugs

Ramón-Patiño, J. L., Schmid, S., Lau, S. C. M., Seymour, L., Gaudreau, P.-O., Li, J. J. N., Bradbury, P. A., & Calvo, E. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004849 · Cited by 39 · see citing works

Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China

Shi, C., Li, Y., Yang, C., Qiao, L., Tang, L., Zheng, Y., Chen, X., Qian, Y., Yang, J., Wu, D., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.946861 · Cited by 39 · see citing works

Targeting the lipid kinase PIKfyve upregulates surface expression of MHC class I to augment cancer immunotherapy

Bao, Y., Qiao, Y., Choi, J. E., Zhang, Y., Mannan, R., Cheng, C., He, T., Zheng, Y., Yu, J., Gondal, M. N., et al. (2023) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314416120 · Cited by 39 · see citing works

Renal Cell Carcinoma: the Oncologist Asks, Can PSMA PET/CT Answer?

Pozzessere, C., Bassanelli, M., Ceribelli, A., Rasul, S., Li, S., Prior, J. O., & Cicone, F. (2019) · Current Urology Reports · doi:10.1007/s11934-019-0938-9 · Cited by 37 · see citing works

Systemic Immune Activation and Responses of Irradiation to Different Metastatic Sites Combined With Immunotherapy in Advanced Non-Small Cell Lung Cancer

Wu, M. J., Liu, J., Wu, S., Liu, J., Wu, H., Yu, J., & Meng, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.803247 · Cited by 38 · see citing works

Imaging of Merkel Cell Carcinoma: What Imaging Experts Should Know

Akaike, G., Akaike, T., Fadl, S., Lachance, K., Nghiem, P., & Behnia, F. (2019) · Radiographics · doi:10.1148/rg.2019190102 · Cited by 37 · see citing works

Immunotherapy Monitoring with Immune Checkpoint Inhibitors Based on [18F]FDG PET/CT in Metastatic Melanomas and Lung Cancer

Lopci, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10215160 · Cited by 31 · see citing works

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma

Govindan, R., Aggarwal, C., Antonia, S. J., Davies, M. J., Dubinett, S. M., Ferris, A. A., Forde, P. M., Garon, E. B., Goldberg, S. B., Hassan, R., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003956 · Cited by 40 · see citing works

Serum Metabolite Biomarkers Predictive of Response to PD-1 Blockade Therapy in Non-Small Cell Lung Cancer

Nie, X., Xia, L., Gao, F., Liu, L., Yang, Y., Chen, Y., Duan, H., Yao, Y., Chen, Z., Lü, S., et al. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.678753 · Cited by 36 · see citing works

Immunotherapy for Aggressive and Metastatic Pituitary Neuroendocrine Tumors (PitNETs): State-of-the Art

Feola, T., Carbonara, F., Verrico, M., Crescenzo, R. M. D., Gianno, F., Colonnese, C., Arcella, A., Alcubierre, D. D., Tomao, F., Esposito, V., et al. (2022) · Cancers · doi:10.3390/cancers14174093 · Cited by 36 · see citing works

PET/CT molecular imaging in the era of immune-checkpoint inhibitors therapy

Gao, Y., Wu, C., Chen, X., Ma, L., Zhang, X., Chen, J., Liao, X., & Liu, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1049043 · Cited by 36 · see citing works

An 89Zr-HDL PET Tracer Monitors Response to a CSF1R Inhibitor

Mason, C. A., Kossatz, S., Carter, L. M., Pirovano, G., Brand, C., Guru, N., Pérez‐Medina, C., Lewis, J. S., Mulder, W. J. M., & Reiner, T. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.230466 · Cited by 35 · see citing works

Immunotherapy to Avoid Orbital Exenteration in Patients With Cutaneous Squamous Cell Carcinoma

McLean, L. S., Lim, A., Webb, A., Cavanagh, K., Thai, A., Magarey, M., Fox, C., Kleid, S., & Rischin, D. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.796197 · Cited by 33 · see citing works

NSCLC Biomarkers to Predict Response to Immunotherapy with Checkpoint Inhibitors (ICI): From the Cells to In Vivo Images

Liberini, V., Mariniello, A., Righi, L., Capozza, M., Delcuratolo, M. D., Terreno, E., Farsad, M., Volante, M., Novello, S., & Deandreis, D. (2021) · Cancers · doi:10.3390/cancers13184543 · Cited by 32 · see citing works

Prognostic value of volumetric PET parameters at early response evaluation in melanoma patients treated with immunotherapy

Nakamoto, R., Zaba, L. C., Rosenberg, J., Reddy, S. A., Nobashi, T. W., Davidzon, G., Aparici, C. M., Nguyen, J., Moradi, F., Iagaru, A. H., et al. (2020) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-020-04792-0 · Cited by 32 · see citing works

Real-world response assessment of immune checkpoint inhibition: comparing iRECIST and RECIST 1.1 in melanoma and non-small cell lung cancer patients

Nelles, C., Graef, C. M., Bernard, P., ten Persigehl, T., Hokamp, N. G., Zopfs, D., Maintz, D. C., Kreuzberg, N., Wolf, J., Bröckelmann, P. J., et al. (2024) · European Radiology · doi:10.1007/s00330-024-11060-4 · Cited by 15 · see citing works

Revisiting RECIST: the case of treatment beyond progression

DAUD, A. I. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30007-x · Cited by 3 · see citing works

Immune-Modified Response Evaluation Criteria in Solid Tumors

National Cancer Institute (2020) · Definitions · doi:10.32388/k8a4i2

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival

Manitz, J., D’Angelo, S. P., Apolo, A. B., Eggleton, S. P., Bajars, M., Bohnsack, O., & Gulley, J. L. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003302 · Cited by 41 · see citing works

Evaluation of non-classical response by immune-modified RECIST and efficacy of atezolizumab beyond disease progression in advanced NSCLC: Results from the randomized Phase II study POPLAR

Artal, A., Mazières, J., Fehrenbacher, L., Rittmeyer, A., Spira, A. I., Park, K., Lewanski, C. R., Liu, S., Ballinger, M., & Vansteenkiste, J. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx091.016 · Cited by 7 · see citing works